摘要
目的:利用溶瘤腺病毒CNHK500体外转染内皮祖细胞,评估其在体外对肺腺癌细胞的特异性杀伤作用。方法:通过溶瘤腺病毒CNHK500转染内皮祖细胞,构建携带CNHK500的内皮祖细胞,并将内皮祖细胞和CNHK500分为三组,即CNHK500组,转染CNHK500的内皮祖细胞组和内皮祖细胞组,分别感染肺腺腺癌细胞A549,用MTT法检测不同肺腺癌细胞A549的生长抑制情况。结果:成功的分离并培养、鉴定内皮祖细胞,并完成CNHK500对内皮祖细胞的转染,CNHK500滴度为2.0×107 pfu/m L,其中CNHK500组肺腺癌细胞A549的存活率为(75.54±5.46)%,转染CNHK500的EPCs组肺腺癌细胞A549的存活率为(80.81±3.69)%,EPCs组肺腺癌细胞A549的存活率为(98.13±2.98)%。结论:本实验首次成功的将CNHK500转染内皮祖细胞,并应用于肺腺癌细胞的生长抑制中,这将有助于为肺腺癌的生物治疗提供一个崭新的策略。
Objective: By means of transfeeting oncolytic adenovirus CNHK500 into endothelial progenitor cells in vitro, its effect of inhibiting the growth of lung adenoeareinoma cells can be observed and evaluated. Methods: The endothelial progenitor cells loaded with CNHK500 were acquired through the transfection of EPCs by CNHK500, and then were divided into three groups, CNHK500, en- dothelial progenitor cells transfeeted by CNHK500 and endothelial progenitor cells. MTT assay was performed to determine the inhibitory effect on lung adenocarcinoma cells. Results: Endothelial progenitor cells were isolated, cultured, identified and transfected by CNHK500 successfully, and CNHK500 titer was 2 × 10^7 pfu/mL, in which, lung adenocarcinoma cells A549 survival rate of CNHK500 group was (75.54±5.46)%, lung adenocarcinoma cells A549 survival rate ofEPCs transfected by CNHK500 group was (80.81±3.69)%, lung adenocarcinoma cells A549 survival rate of EPCs group was (98.13±2.98)%. Conclusions: In this study, CNHK500 was successfully applied to kill lung adenocarcinoma cells by using endothelial progenitor cells as the carrier, which could provide a new strategy for tar- geted therapy of lung adenocarcinoma cells.
出处
《现代生物医学进展》
CAS
2016年第13期2405-2408,2429,共5页
Progress in Modern Biomedicine
基金
国家自然科学基金项目(30901476)
关键词
溶瘤腺病毒
内皮祖细胞
肺腺癌
凋亡
载体
Oncolytic adenovirus
Endothelial progenitor cells
Lung adenocarcinoma cell
Apoptosis
Carrier